The role of p53 in human cancer

Journal of Neuro-Oncology

Volumn 51, Issue 3, 2001, Pages 231-243

  Malkin, David ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Apoptosis; DNA repair; Growth arrest; p53; Tumor suppressor gene

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P19; PROTEIN P53; PROTEIN P73;

AMINO ACID SEQUENCE; APOPTOSIS; BIOCHEMISTRY; CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; DNA REPAIR; FAMILIAL CANCER; GENE MUTATION; GENE THERAPY; GERM LINE; HUMAN; MISSENSE MUTATION; MULTIGENE FAMILY; NONHUMAN; PHENOTYPE; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; MUTATION; NEOPLASMS; PEDIGREE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035006916     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010636426860     Document Type: Review

References (143)

1. Lane DP, Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263, 1979
2. Linzer DI, Levine AJ: Characterization of a 54K dalton cellular tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52, 1979
3. p53 in Dundee website - www.dundee.ac.uk/pathology/ p53.htm
4. Protein interactions with p53 - www.dundee.ac.uk/ pathology/p53inter.htm
5. 9th p53 Workshop - www.athens.wistar.upenn.edu/∼p53/
6. p53 researchers - www.athens.wistar.upenn.edu/∼p53/ dirfp.html
7. p53 database at IARC - www.iarc.fr/p53/homepage.htm
8. p53 database at Institut Curie - perso.curie.fr/Thierry. Soussi/index.html
9. Weizmann Institute p53 site - www.bioinformatics/ weizmann.ac.il/hotmolecbase/entries/p53.htm
10. p53 structure - www.pds.med.umich.edu/users/frank/logo. html
11. p53 database - www.biomedcomp.com/4d.acg$tsrchname? Name = p53
12. Apotosis sites - www.access.digex.net/∼regulate/apolist. html
13. OMIM p53 site - www3.sncbi.nlm.nih.gov/htbin-post/ Omim/dispmim?191170
14. OMIM mdm2 site - www.ncibi.nlm.nih.gov/htbin-post.Omim/dispmim?164785
15. Mdm2 database - www.infosci/coh.org/mdm2asp/ default.asp
16. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
17. Prives C, Hall PA: The p53 pathway. J Pathol 187: 112-116, 1999
18. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455, 1996
19. Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71: 747-752, 1969
20. Li FP, Fraumeni JF Jr: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43: 1365-1373, 1969
21. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990
22. Malkin D: The Li-Fraumeni syndrome. In: Vogelstein B, Kinzler KW (eds) Genetic Basis of Human Cancer 1st Edition. McGraw-Hill, Inc. New York, pp. 393-412
23. Soussi T, Caron de Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-951, 1990
24. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. New Engl J Med 329: 1318-1323, 1993
25. Cariello NF, Cui L, Beroud C, Soussi T: Database and software for the analysis of mutations in the human p53 gene. Cancer Res 54: 4454-4459, 1994
26. Lu H, Levine AJ: Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci USA 92: 5154-5158, 1995
27. Lin J, Wu X, Chen J, Chang A, Levine AJ: Functions of the p53 protein in growth regulation and tumor suppression. Cold Spring Harb Symp Quant Biol 59: 215-223, 1994
28. May P, May E: Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621-7636, 1999
29. Wang Y, Prives C: Increased and altered DNA binding of human p53 by S and G1/M but not G1 cyclin-dependent kinases. Nature 376: 88-91, 1995
30. Dang CV, Lee WM: Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. J Biol Chem 264: 18019-18023, 1989
31. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH: Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18: 5690-5698, 1998
32. Varshavsky A: The ubiquitin system. Trends Biochem Sci 22: 383-387, 1997
33. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992
34. Barak Y, Juven T, Haffner R, Oren M: mdm expression is induced by wild-type p53 activity. EMBO J 12: 461-468, 1993
35. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic lethality in Mdm-2 deficient mice by absence of p53. Nature 378: 206-208, 1995
36. Ljungman M: Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2: 208-225, 2000
37. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346, 1994
38. Clore GM, Omichinski JF, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM: High-resolution structure of the oligomerization domain of p53 by mutidimensional NMR. Science 265: 386, 1994
39. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH: Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct Biol 1: 877, 1994
40. Kussie PH, Gorina S, Marechal V, et al.: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948, 1996
41. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet 7: 480, 1994
42. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA: Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 55: 1146, 1995
43. Knippschild U, Oren M, Deppert W: Abrogation of wild-type p53-mediated growth inhibition by nuclear exclusion. Oncogene 12: 1755, 1996
44. Moll UM, Ostermeyer AG, Haladay AG, Windfield B, Frazier M, Zambetti G: Cytoplasmic sequestration of wild-type p53 protein impairs G1 checkpoint after DNA damage. Mol Cell Biol 16: 1126, 1996
45. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
46. Lakin ND, Jackson SP: Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655, 1999
47. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12: 2831-2841, 1998
48. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972
49. Salvasen GS, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell 91: 443-446, 1997
50. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ: A p53-dependent mouse spindle checkpoint. Science 267: 1353, 1995
51. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF: Abnormal centrosome amplification in the absence of p53. Science 271: 1744, 1996
52. Pines J: p21 inhibits cyclin shock. Nature 369: 520, 1994
53. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523, 1992
54. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847, 1993
55. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957, 1993
56. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86: 8763, 1984
57. Gottlieb T, Oren M: p53 in growth and neoplasia. Biochem Biophys Acta Rev Cancer 1287: 77, 1996
58. Fan S, Smith MK, Rivet DJ, Duba D, Zhan Q, Kohn K, Fornace AJ, O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649, 1995
59. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345, 1991
60. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild-type p53 in a human colon tumour-derived cell line. Proc Natl Acad Sci USA 89: 4495, 1992
61. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849, 1993
62. Miyashita T, Reed TC: Tumour suppressor p53 is a direct transcriptional activator of the human bax gene: Cell 80: 293, 1995
63. Miyashita T, Krajewski S, Krajewski H, et al.: Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799, 1994
64. Canman CE, Griber T, Coutts S, Kastan MB: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9: 600-611, 1995
65. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10: 1945-1952, 1996
66. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, Borner C: Bcl-2 proloongs cell survival after Bax-induced release of cytochrome c (see comments). Nature 391: 496-499, 1998
67. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES: Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1: 949-957, 1998
68. Knudson CM, Tung KS, Tourtelotte WG, Brown GA, Korsmeyer SJ: Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270: 96-99, 1995
69. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW: NK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13: 2670-2677, 1999
70. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Kranz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, ed-Deiry WS: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143, 1997
71. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995
72. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M: A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 16: 4384-4392, 1997
73. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 389: 300-305, 1997
74. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362, 1988
75. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Li FP: Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51: 6094-6097, 1991
76. Garber JE, Burke EM, Lavally BL, et al.: Choroid plexus tumors in the breast cancer-sarcoma syndrome. Cancer 66: 2658-2660, 1990
77. Horio Y, Suzuki H, Ueda R, et al.: Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 9: 1231-1235, 1994
78. Varley JM, Evans DG, Birch JM: Li-Fraumeni syndrome -a molecular and clinical review. Br J Cancer 76: 1-14, 1997
79. Varley JM, McGown G, Thorncroft M, et al.: Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57: 3245-3252, 1997
80. Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90: 606-611, 1998
81. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990
82. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989
83. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A: High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9: 3982-3991, 1989
84. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni JF Jr, Li FP, Friend SH: Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56: 608-615, 1995
85. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H: Tumours associated with p53 germline mutations: a synopsis of 91 families. Amer J Pathol 150: 1, 1997
86. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris-Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell E, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298, 1994
87. Srivastava S, Zou Z, Pirollo K, Blattner W, Cheng EH: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747, 1990
88. Eeles RA: Germline mutations in the p53 gene. In: Ponder BAJ, Cavenee WK, Solomon E (eds) Cancer Surveys: Genetics and Cancer: A Second Look Cold Spring Harbor Laboratory Press 101-124, 1995
89. Barel D, Avigad S, Mor C, Fogel M, Cohen IJ, Zaizov R: A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family. Cancer Genet Cytogenet 103: 1, 1998
90. Bell DW, Varley JM, Szydlo TE, et al.: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528-2531, 2000
91. Hirao Z, Kong YY, Matsuoka S, et al.: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824-1827, 2000
92. www.sciencemag.org/cgi/content/full/289/5478/359a
93. Donehower LA, Harvey M, Slagle BL, et al.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221, 1992
94. Jacks T, Remington L, Williams BO, et al.: Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7, 1994
95. Purdie CA, Harrison DJ, Peter A, et al.: Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9: 603-609, 1994
96. Venkatachalam S, Shi YP, Jones SN, et al.: Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote tumor formation. EMBO J 17: 4657-4667, 1998
97. Varley JM, Thorncroft M, McGown G, Tricker K, Birch JM, Evans DG: A novel deletion within exon 6 of TP53 in a family with Li-Fraumeni-like syndrome, and LOH in a benign lesion from a mutation carrier. Cancer Genet Cytogenet 90: 14-16, 1996
98. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D: High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86: 1707-1710, 1994
99. Varley JM, McGown G, Thorncroft M, et al.: Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65: 995-1006, 1999
100. McIntyre JF, Smith-Sorensen B, Friend SH, et al.: Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12: 925-930, 1994
101. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D: Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95: 1606-1611, 1995
102. Moutou C, Le Bihan C, Chompret A, et al.: Genetic transmission of susceptibility to cancer in families of children with soft tissue sarcomas. Cancer 78: 1483-1491, 1996
103. Borresen A-L, Andersen TI, Garber J, et al.: Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234-3236, 1992
104. Sidransky D, Tokino T, Helzlsouer K, et al.: Inherited p53 gene mutations in breast cancer. Cancer Res 52: 2984-2986, 1992
105. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 14: 1730-1736, 1996
106. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55: i-iv, 1994
107. Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J, Malkin D, Li FP: p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene 18: 3970, 1999
108. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhatter J: A simple p53 functional assay for screening cell lines, blood and tumours. Proc Natl Acad Sci USA 92: 3963, 1995
109. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM: Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17: 1061, 1998
110. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA: A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nature Genet 9: 305, 1995
111. Lee JM Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742, 1993
112. Lee JM, Abrahamson JLA, Kandel R, Donehower L, Bernstein A: Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53-deficient mice. Oncogene 9: 3731, 1994
113. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG: A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet 10: 181, 1995
114. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn LM: Oxidative damage in chemical teratogenesis. Mutat Res 12: 65, 1997
115. Ramqvist T, Magnusson K, Wang Y, Szeley L, Klein G: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8: 1495-1500, 1993
116. Show P, Bovey R, Tardy S, Sahli R, Sordat B, Cost J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992
117. Hamada K, Alemany R, Zhang WW, Hittelman WN, Lotan R, Roth JA, Mitchell MF: Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 56: 3047-3054, 1996
118. Pirollo KF, Hao Z, Rait A, Jang YJ, Fee WE, Ryan P, Chiang Y, Chang EH: p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 14: 1735-1746, 1997
119. Clayman GL, Frank DK, Bruso PA, Goepfert H: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5: 1715-1722, 1999
120. Li JH, Lax SA, Kim J, Klamut H, Liu FF: The effect of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 43: 607-616, 1999
121. Badie B, Kramar MH, Lau R, Boothman DA, Economou JS, Black KL: Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neuro-Oncol 37: 217-222, 1998
122. Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F, Bolliger CT, Kauczor HU, Dalquen P, Fritz MA, Swanson S, Herrmann R, Huber C: A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Therapy 9: 2075-2082, 1998
123. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996
124. Pennisi E: Training viruses to attack cancers. Science 282: 1244-1246, 1998
125. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D, Kirn D: ONYX-015, and E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645, 1997
126. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997
127. Kaelin WG: The p53 gene family. Oncogene 18: 7701-7705, 1999
128. Schmale S, Bamberger C: A novel protein with strong homology to the tumour suppressor p53. Oncogene 15: 1363-1367, 1997
129. Osada M, Ohba M, Kawahara C, et al.: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 4: 839-843, 1998
130. Senoo M, Seki N, Ohira M, et al.: A second p53 related protein, p73L, with homology to p73. Biochem Biophys Res Commun 248: 603-607, 1998
131. Yang A, Kaghad M, Wang Y, et al.: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death inducing and dominant negative activities. Molecular Cell 2: 305-316, 1998
132. Jost CA, Marin MC, Kaelin WG: p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997
133. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JY: The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809, 1999
134. Agami R, Blandino G, Oren M, Shaul Y: Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 399: 809-813, 1999
135. Takada N, Ozaki T, Ichimaya S, Todo S, Nakagawara A: Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Res 59: 2810-2814, 1999
136. Ichimaya S, Nimua Y, Kageyama H, Takada N, Sunahara M, Shishikura T, Nakamura Y, Sakiyama S, Seki N, Ohira M, Kaneko Y, McKeon F, Caput D, Nakagawara A: p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18: 1061-1066, 1999
137. Mihara M, Nimura Y, Ichimaya S, Sakiyama S, Kajikawa S, Adachi W, Amano J, Nakagawara A: Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma. Br J Cancer 79: 164-167, 1999
138. Tsujimoto T, Mochizuchi S, Iwadate Y, Namba H, Nagai M, Kawamoto T, Sunahara M, Yamamura A, Nakagawara A, Sakiyama S, Tagawa M: The p73 gene is not mutated in oligodendrogliomas which frequently have a deleted region at chromsome 1p36.3. Anticancer Res 20: 2495-2497, 2000
139. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W: Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 39: 94-100, 1999
140. Marin MC, Kaelin WG: p63 and p73: old members of a new family. Biochem Biophys Acta 17: M93-M100, 2000
141. Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL, Cox LS, Poon RY: MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 9: 829-832, 1999
142. White E, Prives C: DNA damage enables p73. Nature 399: 734-737, 1999
143. Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H: Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 99: 143-153, 1999.